ImmuPharma (LON:IMM) Announces Quarterly Earnings Results

ImmuPharma (LON:IMM) released its quarterly earnings data on Wednesday. The company reported GBX (0.37) EPS for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 6,634.51% and a net margin of 3,519.56%.

ImmuPharma Stock Performance

LON IMM opened at GBX 4.70 on Wednesday. ImmuPharma has a one year low of GBX 1.39 and a one year high of GBX 19.40. The stock has a 50-day moving average of GBX 4.63 and a 200 day moving average of GBX 6.31. The company has a market capitalization of £29.29 million, a price-to-earnings ratio of -5.28 and a beta of 2.98.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.